Light therapy during TIL treatment for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests a special bright light therapy designed to help your body's natural sleep-wake cycle. It is being studied for people with advanced melanoma who are about to receive TIL therapy, a treatment that uses your own immune cells to fight the cancer. The light therapy might help improve how you feel during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be able to read and understand English to fill out questionnaires.
- Your melanoma must have continued to progress after treatment with immune checkpoint inhibitors (like Keytruda or Opdivo).
- You must be eligible for standard TIL therapy (also called lifileucel or Amtagvi) and have signed consent for it.
- You should not have certain sleep or eye conditions, or take sleep aids like melatonin or zolpidem, in the two weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using your own immune cells to fight advanced melanoma. The cells are taken from a tumor, grown in a lab, and given back to you either near the tumor or throughout your body.
This study tests if daily bright light therapy can help people with advanced melanoma or lung cancer feel better during their first immunotherapy treatment. The light box is used at home for a short time each morning.
This trial tests a treatment called tumor-infiltrating lymphocyte (TIL) therapy for people with advanced melanoma that has not responded to immune checkpoint inhibitors. TIL therapy uses your own immune cells to fight the cancer. The study aims to see if this can help shrink tumors or slow the disease.
This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
This study tests a new type of cell therapy made from your own immune cells (called TILs) to see if it can shrink tumors better than standard chemotherapy in people with advanced melanoma that has stopped responding to immunotherapy. If you qualify, you may have a chance to try a personalized treatment that uses your body's own defenses to fight the cancer.
Hear when a new Clinical Stage III Cutaneous Melanoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.